The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
about
Deficiency in Aryl Hydrocarbon Receptor (AHR) Expression throughout Aging Alters Gene Expression Profiles in Murine Long-Term Hematopoietic Stem CellsInvestigating core genetic-and-epigenetic cell cycle networks for stemness and carcinogenic mechanisms, and cancer drug design using big database mining and genome-wide next-generation sequencing dataMolecular interactions of polo-like kinase 1 in human cancers.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.PLK4: a link between centriole biogenesis and cancer.Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia.
P2860
The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The deregulated promoter methy ...... in hematological malignancies.
@en
The deregulated promoter methy ...... in hematological malignancies.
@nl
type
label
The deregulated promoter methy ...... in hematological malignancies.
@en
The deregulated promoter methy ...... in hematological malignancies.
@nl
prefLabel
The deregulated promoter methy ...... in hematological malignancies.
@en
The deregulated promoter methy ...... in hematological malignancies.
@nl
P2093
P2860
P1433
P1476
The deregulated promoter methy ...... in hematological malignancies
@en
P2093
Alejandra Ward
Brayden C Labute
Caroline Hamm
David Shum
John W Hudson
Sindu Kanjeekal
P2860
P304
P356
10.3109/10428194.2014.971407
P577
2015-01-24T00:00:00Z